Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DK-19-028

Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

Closed on November 3, 2020.

Posted
December 10, 2019
Close date
November 3, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $300,000 in first-year total cost, median $300,000.

Most frequent study sections

  1. Special Emphasis Panel[ZDK1 GRB-J (M2)]1

Most frequent institutions

  1. MINUTIA, INC.1
Competing awards under RFA-DK-19-028 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Real-time intracellular monitoring of microRNAs in human stem cell-derived insulin producing organoids1R43DK130034-01DIGOVICH, CATHERINEHEBROK, MATTHIASPURI, SAPNAVO-DINH, TUANMINUTIA, INC., CA$300,000ZDK1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DK-19-028: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed) | ScienceDex | ConductScience